To delineate interactions of infused tissue-type plasminogen activator (t-PA) with inhibitors in plasma and their impact on fibrinolytic activity, serial plasma samples from patients with acute myocardial infarction and from normal rabbits given infusions of t-PA were assayed for t-PA antigen, activity of "fast acting" plasminogen activator inhibitor (PAI-1), and the presence and nature of t-PA-inhibitor complexes. In patients, endogenous t-PA circulated predominantly as a 100 kilodalton (kDa) complex with PAI-1, as verified by immunoprecipitation. During infusions, t-PA circulated not only as free t-PA (55 kDa) but also in complexes with PAI-1 (100 kDa), cx2-antiplasmin (110 kDa), and C,-esterase inhibitor (170 kDa). After termination of infusions, levels of free t-PA declined, while inhibitor complexes remained prominent. Free PAI-1 activity, assayed spectrophotometrically, was markedly elevated in the 24 hr interval after infusion of t-PA in 47% of patients with infarction. The specific activity of t-PA during infusions was 0.4 IU/ng or greater. However, during the 3 hr interval after infusions in patients, specific activity declined in association with prominence of t-PA complexes, predominantly with PAI-1. Infusions of t-PA in normal rabbits did not result in reactive increases in PAI-1 activity or in the t-PA-PAI-1 complex. After infusions, t-PA was associated predominantly with o2-antiplasmin and C1-esterase inhibitor rather than PAI-1. t-PA inhibitor complexes were seen despite immediate acidification of whole blood, indicating that they were present in vivo. Thus: (1) infused t-PA initially saturates PAI-1 and circulates as free t-PA and in complexes with protease inhibitors, predominantly C1-esterase inhibitor and Ux2-antiplasmin, (2) increased PAI-1 activity associated with infarction attenuates t-PA activity after infusions even though immunoreactive t-PA concentrations exceed pretreatment values, (3) fibrinolytic activity is not necessarily proportional to total t-PA after infusions, and (4) monitoring and modulation of PAI-1 is likely to be useful clinically. Circulation 77, No. 3, 660-669, 1988. CORONARY THROMBOLYSIS is a useful intervention in the early treatment of acute transmural myocardial infarction. Tissue-type plasminogen activator (t-PA) is a particularly effective agent for this purpose and one that exhibits biochemical properties accounting for a high therapeutic-to-toxic ratio. 1-3 From a' practical point of view, reocclusion after initially successful coronary clot lysis is an important potential limitation of thrombolytic therapy that is not completely prevented even with therapeutic doses of relationship between plasminogen activator inhibitors from different sources. Thromb Haemost 57: 29, 1987 37. Rijken DC, Emeis JJ: Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats. Biochem
heparin.4 Its incidence within 10 days after coronary thrombolysis varies from 20% to 45% when infusions of t-PA are given over 3 hr. Prolonged low-dose infusions of t-PA appear to decrease its rate significantly.5' 6 Increased understanding of factors potentially predisposing to this phenomenon is needed so that effective strategies can be developed to reduce its incidence further. This study was performed to determine the extent to which interactions of t-PA with inhibitors occur that could attenuate functional activity of t-PA during and after infusions, thereby potentially contributing to coronary reocclusion.
Fast-acting plasminogen activator inhibitors (PAI-1) have been demonstrated in plasma, platelets, and conditioned media of endothelial cells and hepatocytes.7-12 PAI-1 activity behaves as an acute phase reactant. 13 14 Increases occur in association with deepvein thrombosis, age, hypertriglyceridemia, pregnancy, septicemia, and surgery.)4-18 Increased PAI-1 LABORATORY INVESTIGATION-CORONARY THROMBOLYSIS activity has been implicated as the cause of reduced fibrinolytic capacity of plasma from young survivors of myocardial infarction, a finding postulated by some to have potential pathogenic significance. 19 t-PA in plasma forms complexes with PAI-1 and with other lower affinity protease inhibitors, predominantly C1-esterase inhibitor and cx2-antiplasmin.9' [20] [21] [22] We hypothesized that interactions of t-PA with one or more plasma protease inhibitors may compromise fibrinolytic activity during or after infusion of t-PA, thereby potentially contributing to reocclusion. Accordingly, fibrinolytic activity, free PAI-1 activity, and t-PA complexes with PAI-1 and other inhibitors were characterized sequentially in plasma samples during and after infusions of t-PA in patients with acute myocardial infarction. The results indicate that infused t-PA initially saturates PAI-1 and circulates as free t-PA and in complexes with Cl-esterase inhibitor and ct2-antiplasmin. During infusions of t-PA, fibrinolytic activity is maintained despite complexes of t-PA with plasma protease inhibitors. However, after infusions increased PAI-1 activity associated with myocardial infarction markedly attenuates the fibrinolytic activity of residual, immunoreactive t-PA.
Methods
Materials. Human melanoma t-PA (Bowes cell line, predominantly one-chain t-PA), human fibrinogen (> 90% clottable protein), human plasminogen (predominantly glnplasminogen), and the synthetic chromogenic substrate D-Val-Leu-Lys-pNA (S-2251) were purchased from Helena Laboratories, Beaumont, TX. CNBr-digested fibrinogen used as catalyst in the PAI-1 spectrophotometric assay was prepared as described by Verheijen et al. 23 Human t-PA produced by recombinant DNA technology and expressed in a Chinese hamster ovary cell system was provided by Genentech Inc., South San Francisco. Bovine fibrinogen (> 95% clottable protein, plasminogen, and thrombin free) was purchased from Calbiochem, La Jolla, CA. Reagents used in ELISA assays, purified polyclonal goat immunoglobulin G (IgG) to human melanoma t-PA, and mouse monoclonal IgG to PAI-1 were obtained from American Diagnostica, Greenwich, CT. Bovine thrombin (600 NIH units/mg protein), antisera, and reagent grade chemicals were obtained from Sigma Chemical Co., St Experimental animals. New Zealand white rabbits weighing 2.5 to 3.5 kg were anesthetized with intramuscular injections of xylazine (20 mg/kg) and ketamine (60 mg/kg) sufficient for maintenance of analgesia and anesthesia for 1.5 to 2.0 hr. Subsequently, additional intravenous injections of both were administered as necessary to maintain adequate analgesia and anesthesia. Five rabbits were given 0.5 mg of t-PA by intravenous bolus injection followed by 2 mg/kg infusions over 1 hr. Four controls were given 0.9% saline administered similarly via the right femoral vein. Volumes of injection were identical for both groups. Arterial blood samples were obtained before administration of t-PA or saline, and hourly for 4 hr during and after the termination of infusions. All reagents were nonpyrogenic. Administration of anesthesia, t-PA, and saline, and acquisition of blood samples was performed under rigorously aseptic conb ditions to avoid effects of endotoxin contamination potentially leading to elevations of plasma PAL-18
Patients. Blood samples were obtained from 47 human subjects, 24 of whom were subjects without acute cardiac disease. Serial plasma samples for PAI-1 activity and fibrin autography were obtained from 23 patients with acute cardiac disease. Twenty-one were patients with acute myocardial infarction, and 17 were treated with intravenous t-PA (16 men, one woman, 55 + 11 years of age, with anterior [n = 101 or inferior [n = 7] transmural myocardial infarction). t-PA was administered intravenously as an initial 6 mg bolus and decremental infusion of a total dose of 100 mg over 6 hr (60, 20, 5, 5, 5, 5 mg/hr) with concomitant administration of 5000 units of heparin intravenously followed by 1000 units/hr for 5 days. Four were patients with infarction treated conventionally without thrombolytic agents or heparin (two men and two women, 69 ± 9 years of age; three had anterior infarction and one had inferior infarction in one). Two other patients had angiographically documented coronary artery disease manifested by progressive angina without infarction which was excluded by serial plasma enzyme determinations during hospitalization in the Coronary Care Unit (both men, average age 64 years).
Isolated plasma samples for PAI-1 activity were obtained during the interval from 8:00 A.M. to 11:00 A.M. from 24 additional subjects including: adults without acute medical illness (n = 13, nine men, four women, 28 + 4 years of age), hospitalized patients without angiographic evidence of coronary disease (n = 6, three meni, three women, 56 + 10 years of age), and hospitalized patients without infarction but with angiographically documented, clinically stable coronary artery disease (n -5, four men, one woman, 66 + 9 years of age).
Acquisition of blood samples. Venous blood samples were obtained via the antecubital vein with 2.7 ml of whole blood collected into 3.0 ml Vacutainer tubes containing 0.3 ml of 0.129M sodium citrate cooled to 00 to 40 C on ice and centrifuged immediately at 40 C at 2000 g for 20 min. Aliquots of plasma were stored at -700 C for subsequent assay. Before assay samples were thawed rapidly and acidified or diluted in buffer containing sodium dodecyl sulfate (SDS), 1% final concentration, to minimize interaction of t-PA with inhibitors in vitro. For samples obtained from human subjects, acidification of whole blood was performed by directly drawing 2 ml of venous blood into sodium citrate Vacutainer tubes containing 0.8 ml of 1.OM sodium acetate buffer, pH 3.9. For samples from rabbits, 1 ml of citrated whole blood was added to 0.5 ml of sodium acetate buffer. For patients treated with t-PA, plasma samples were obtained immediately before treatment, hourly throughout infusion of t-PA, hourly for 3 hr after completion of infusions, and 24, 48, and 72 hr and 7 days after infusion. Serial samples at selected intervals were obtained from patients with infarction and chest pain without infarction. Blood samples from the other 11 patients with and without coronary artery disease were obtained during hospitalization for coronary angiography.
Electrophoresis. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed with the use of the Laemmli buffer system24 and a mini-Protean II unit (Bio-Rad) on 8 x 7 cm vertical slab gels consisting of separating gels of 7.5% acrylamide and stacking gels of 4.0% acrylamide. Plasma samples were diluted in phosphate-buffered saline (1: 10 or 1:20) to produce an interpretable pattern of lysis on fibrin auto-graphs and were adjusted to a final concentration of 1.0% SDS. Fibrin autography. Fibrin autography was performed on sequential samples from 17 patients according to the method of Granelli-Piperno and Reich. 25 Autography was performed by washing the SDS-PAGE gels with 2.5% Triton X-100 for 1 hr. Gels were then laid carefully on fibrin indicator gels containing final concentrations of the following: 10 mM sodium phosphate and 150 mM sodium chloride, pH 7.5; 1.3% agarose; 2.5 mg/ml fibrinogen; 0.2 NIH unit/ml of thrombin; and supplementation when indicated in the text with 20 ,ug/ml of plasminogen. Incubations were performed in a moist chamber at 370 C for 2 to 18 hr and the duration of incubation was determined by the final concentration of plasminogen in the fibrin indicator gel. Plasminogen-free bovine fibrinogen was substituted for grade L human fibrinogen when plasminogen-free indicator gels were needed. Fibrin autographs were photographed serially with a Polaroid camera.
Activity of PAI-1. PAI-I was quantified in plasma samples from 47 human subjects and nine rabbits with a modification of the spectrophotometric assay developed by Chmielewska and Wiman.26 Predominantly single-chain melanoma t-PA was added to plasma samples to yield a final concentration of 10 IU/mi and residual t-PA activity was determined with S-2251, an amidolytic substrate of plasmin. One arbitrary unit (AU) of PAI-1 is defined as the amount that inhibits one international unit (IU) of t-PA activity over 10 min. Briefly, t-PA was added to plasma samples in a final concentration of 10 IU/mi and was incubated at 25°C for 10 min, followed by acidification with an equal volume of 1.OM sodium acetate buffer, pH 3.9, with a subsequent 15 min incubation at 250 C. Acidified samples were then rapidly frozen at -800 C. An aliquot of the same plasma sample without added t-PA was also assayed to determine background t-PA activity. Standard curves were prepared concomitantly in acidified pooled plasma from young healthy donors. Samples and standards were thawed and diluted 40-fold with 0.05M tris-HCl, pH 8.3, with 0.01% Tween 80 (assay buffer). Selected proportions of the two standards consisting of 0 and 10 AU/mi were mixed to yield a standard curve with PAI-1 equivalent activity ranging from 0 to 10 AU/mi. Residual t-PA activity was assayed with a reaction mixture consisting of final concentrations of 0.30 mM S-2251, 40 Ftg/ml gln-plasminogen, 240 pg/ml CNBr-digested fibrinogen in assay buffer and that was incubated at 370 C for 1.5 hr with agitation. The reaction was terminated with 20% acetic acid and absorbance was determined at 405 nm with a Response Spectrophotometer (Gilford Instrument Laboratories, Oberlin, OH). PAI-1 activity in each sample, corrected for its corresponding plasma blank, was determined with respect to standard curves and expressed as arbitrary units per milliliter. The interassay coefficient of variation of the PAI-1 assay was 4.7 + 1.9%. Determinations of t-PA antigen. The ELISA assay system developed by Bergsdorf et al. 27 with reagents supplied commercially by American Diagnostica was used to determine the concentration of t-PA antigen in plasma samples. The absorbance at 492 nm was determined with an eight-channel scanning spectrophotometer (Titertek Multiskan, Flow Laboratories, Irvine, CA).
Determination of fibrinolytic activity. Preparation of euglobulin fractions and assessments of fibrinolytic activity were performed with a modification of the fibrin plate assay described by Astrup and Mullertz.2" All samples were assayed in duplicate. Planimetry was used to quantify the zones of lysis, which were compared with those obtained with concomitantly assayed standards and expressed as international units per milliliter of t-PA activity. Immunoprecipitation. Immunoprecipitation of t-PA and t-PA-inhibitor complexes was performed with a modification of the method detailed by Wun and Capuano." Briefly, plasma samples were incubated with goat anti-t-PA IgG, goat antiserum to cx-antitrypsin, mouse anti-PAI-1 IgG, or mouse preimmune serum (5 Wg/ml final concentration) for at least 3 hr at 40 C with agitation. Subsequently, donkey antigoat IgG or goat antimouse IgG (50 Lg/ml final concentration) were added to each mixture and incubated for at least 3 hr at 4°C with agitation. Samples were centrifuged for 15 min in a microcentrifuge to precipitate the immunocomplexes. After centrifugation, the precipitates were washed with phosphate-buffered saline and resuspended in buffer containing 0.1M glycine/HCl, pH 2.2, with 0.1% SDS, 6.OM urea, and 0.001% bromophenol blue. Immunoprecipitates were characterized with 7.5% SDS-PAGE and autography with fibrin indicator gels supplemented with plasminogen.
Statistical analyses. Data are expressed as the means + SD. Parametric one-way analysis of variance was used to characterize data from specific groups. A two-way analysis of variance was performed for continuous data. If differences were noted by analysis of variance, a two-tailed unpaired Student's t test was performed to compare differences between groups. Significance was defined at the p < .05 level.
Results
Complexes of t-PA with plasma inhibitors during and after infusions. Figure 1 illustrates representative fibrin autographs of serial samples from two patients obtained before, during, and after administration of t-PA. Before infusion, t-PA in plasma circulated predominantly as a 100 kDa form. During infusions, lytic zones were present in regions corresponding to molecular weights of 55, 100, 110, and 170 kDa. (Another lytic zone was present near the top of the separating gel.) High molecular weight complexes of t-PA were present in samples subjected to immediate acidification of whole blood and were not evident on autographs of purified t-PA (data not shown). Verification that the lytic zones represented t-PA activity was accomplished in two ways, as demonstrated in figure 2 . First, autography with plasminogenfree fibrin indicator gels eliminated all lytic zones, confirming their dependence on activation of plasminogen. Second, immunoprecipitation of plasma samples with goat antihuman t-PA IgG yielded lytic zones at 55, 100, 110, 170 kDa and at the top of the separating gel when analogous forms were present in the sample.
Immunoprecipitation with goat anti-otl-antitrypsin antisera did not elicit any lytic zones.
The 55 kDa lytic zone was confirmed to be free t-PA on the basis of its comigration with the lytic zone seen with purified t-PA (data not shown). Immunoprecipitation of plasma samples with murine monoclonal antibody to PAI-1 confirmed that the 100 kDa lytic zone represented the t-PA-PAI-1 complex. Mouse preimmune serum did not precipitate this lytic zone, as shown in figure 
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The same relationships persisted when samples were diluted serially. During the course of infusions when the dose of infused t-PA per min was declining, decreases in lytic zones associated with free t-PA and t-PA complexes with a2-antiplasmin and Cl-esterase inhibitor were evident. In samples from nine of 17 patients the lytic zone representing complexes of t-PA with (a2-antiplasmin was virtually absent after 2 hr of infusion. The lytic zone associated with the t-PA-PAI-1 complex became progressively prominent with time while zones associated with free t-PA and other complexes were becoming less prominent, as illustrated in figure  3 . In samples from seven patients, zones of lysis associated with t-PA-PAI-1 complexes increased markedly. In samples from six other patients the increases were more modest. In four patients the activity of the complex did not appear to change. In 10 patients the lytic zones associated with free t-PA and the t-PA-PAI-1 complex were comparable immediately after termination of infusion of t-PA. During the 3 hr after infusion of t-PA fibrin autography demonstrated reduction of free t-PA but persistence of t-PA complexes with PAI-1 and Cl-esterase inhibitor. Assays of serially diluted samples confirmed that the activity of the t-PA-PAI-1 complex far exceeded that of the complex of t-PA with C1-esterase inhibitor, suggesting that residual t-PA in the circulation was predominantly in the form of the t-PA-PAI-1 complex.
Plasma fibrinolytic activity and the concentration of t-PA antigen. To determine the effect of PAI-1 and other plasma protease inhibitors on fibrinolytic activity during and after infusion of t-PA, ELISA assays and fibrin Results are expressed as the mean + SD. plate analyses of euglobulin fractions were performed on sequentially obtained samples from patients. Table  1 shows serial changes in the concentration of t-PA antigen and fibrinolytic activity in samples from eight patients treated with t-PA. Both activity and t-PA antigen concentrations varied markedly among patients. Nevertheless, the temporal changes in both were consistent. Before administration of t-PA, only minimal fibrinolytic activity was attributable to immunoreactive t-PA. During administration of t-PA, the ratio of fibrinolytic activity to t-PA antigen concentration was 0.4 IU/ng or greater despite significant amounts of t-PAinhibitor complexes evident on fibrin autographs. After termination of infusion of t-PA, reduction of fibrinolytic activity was apparent, even though the concentration of t-PA antigen markedly exceeded pretreatment values. The marked disparity between fibrinolytic activity and the concentration of t-PA antigen in plasma after infusions is illustrated in figure 4 . Only minimal fibrin plate activity was demonstrable when plasma t-PA concentration was as high as 100 ng/ml within 2 hr after termination of infusion of t-PA. The reduction of specific activity of t-PA (IU/ng) in plasma samples was associated with the disappearance of free t-PA detectable on fibrin autographs and the persistence of t-PA-inhibitor complexes, predominantly with PAI-1. The predominance of 100 kDa complexes with minimal fibrinolytic activity was evident immediately after termination of infusion of t-PA in one patient, 1 hr after termination in four patients, and 2 hr after termination in three patients. The fibrinolytic activity of euglobulin fractions, as assessed by the extent of fibrin plate lysis expressed in square millimeters, was increased for 2 hr after infusion of t-PA Vol. 77, No. 3, March 1988 when compared with pretreatment values. However, the prevailing level of fibrinolytic activity per nanogram of total t-PA (i.e., free plus complexed) was inappropriate and significantly reduced when compared with pretreatment values, as shown in figure 5 .
CIRCULATION
Activity of free PAI-1. Free PAI-1 activity was assessed to facilitate interpretation of fibrin autographs documenting increases in t-PA-PAI-1 complexes with time in patients with acute myocardial infarction given t-PA. PAI-1 activity in samples from the four groups of human subjects evaluated is shown in table 2. PAI-1 activity in samples from older hospitalized patients exceeded that in samples from young nonhospitalized subjects. Although statistically significant differences of mean PAI-1 activity were not apparent among the three groups of hospitalized patients, four patients with acute myocardial infarction exhibited striking elevations of free PAI-1 activity in samples obtained on hospital admission. Serial changes in free PAI-1 activity from patients treated with t-PA and controls are shown in table 3. Sequential samples obtained after infusions of t-PA from 12 of 13 patients exhibiting increases in the t-PA-PAI-1 complex by fibrin autography also exhibited free PAI-1 activity above baseline values. Eight patients (47%) with infarction exhibited striking elevations of free PAI-1 activity within 24 hr after infusion of t-PA. However, average free PAI-1 values after infusion of t-PA were not statistically different from pretreatment values or values in patients with infarction or angina who did not receive t-PA. infused in normal rabbits (n = 5). Mean free PAI-1 activity after infusion of t-PA was not significantly different from preinfusion values or from values in rabbits (n = 4) given infusions of 0.9% saline, as shown in table 4. Fibrin autography revealed predominantly free t-PA with minimal activity of complexes of t-PA with Ox2-antiplasmin and C1-esterase inhibitor.
After infusions, the activity of free t-PA decreased slowly, while complexes persisted, predominantly with Cl-esterase inhibitor and %2-antiplasmin (data not shown). Although complexes of t-PA with PAI-1 were evident 2 hr after infusions, their activity was minimal compared with that of complexes of t-PA with other inhibitors when assessed by serial dilution. These results indicate that in normal rabbits, infusion of t-PA does not produce reactive changes in free PAI-1 activity or the t-PA-PAI-1 complex simulating those in patients with infarction.
Discussion
This study was undertaken to delineate interactions of t-PA with plasma protease inhibitors and their associated effects on fibrinolytic activity during and after infusions in patients with evolving myocardial infarction. Inhibition of t-PA activity by human plasma in vitro occurs in two phases: a "fast phase" manifest by inhibition of t-PA activity within minutes, and a 4'slow phase" manifest by inhibition of t-PA activity over hours.7 Because of the substantial quantities of t-PA administered to patients and the prolonged nature of infusions, we hypothesized that plasma inhibitors responsible for both phases of t-PA inhibition may alter the specific activity of circulating t-PA during or after infusions.
The results indicate that t-PA circulates in association with several plasma proteins, acknowledged to be protease inhibitors. Fibrin autography of serial plasma samples exhibited that administered t-PA rapidly saturates available PAI-1 and that excess t-PA forms complexes with inhibitors of low affinity, perhaps contributing to prevention of intravascular proteolysis. Immediate acidification of whole blood does not preclude detection of t-PA inhibitor complexes, confirming their presence in the circulation in vivo. During the course of infusions of t-PA, declining concentrations of t-PA in plasma are associated with decreasing concentrations of complexes of t-PA with a2-antiplasmin and C1-esterase inhibitor. In contrast, the concentration of complexes of t-PA with PAI-1 remains constant or increases. These results are consistent with those of Wun and Capuano,21 who have demonstrated recruitment of t-PA inhibitors in pooled human plasma in vitro. They showed that fibrin autographs of t-PAdepleted plasma samples reconstituted with small amounts of t-PA (10 ng/ml) exhibited predominantly the t-PA-PAI-1 complex despite prolonged incubations. Additions of larger amounts of t-PA, up to 50 PAI-I activity expressed in AU/mi in serial plasma samples fron refers to baseline or preinfusion sample. AMI = acute myocardial infarction. ng/ml, resulted in formation of additional complexes with (o2-antiplasmin and Cl-esterase inhibitor. 21 The absence of complexes of t-PA with 0x2-antiplasmin after 2 hr of thrombolytic therapy in 53% of patients is consistent with depletion of (x2-antiplasmin associated with generation of plasmin in the circulation by administered t-PA.1 Evaluation of fibrinolytic activity indicated that during infusions of t-PA, the specific activity of t-PA remained typical of that of t-PA in buffer, despite the presence of complexes of t-PA with plasma inhibitors. This may reflect the overwhelming effects of high concentrations of t-PA produced in plasma by pharmacologic doses. After termination of infusion of t-PA, levels of free t-PA declined. In contrast, t-PA complexes persisted. Although the excess of free t-PA with respect to inhibitor complexes during infusions precluded attenuation of functional activity, the functional significance of t-PA complexes with inhibitors after Vol. 77, No. 3, March 1988 ,17 of whom were treated with t-PA. Time zero infusions was substantial. The reduced fibrinolytic activity evident in euglobulin fractions of samples with these autographic characteristics confirms that the complexes were associated with true inhibition of t-PA.
Serial dilution of samples obtained hourly after cessation of infusion of t-PA confirmed that residual t-PA was predominantly complexed to PAI-1 and compar- ison with corresponding ELISA values indicated that as much as 100 ng/ml of t-PA was inhibited.
Overall, fibrinolytic activity was modestly increased for 2 hr after termination of infusion when compared with pretreatment values, as noted previously.29 However, the prevailing level of fibrinolytic activity was not proportional to the overall concentration of t-PA in plasma and was significantly reduced with respect to plasma t-PA concentrations. Thus, the prevailing level of t-PA activity after infusion of t-PA in patients with myocardial infarction may be overestimated by results of t-PA antigen assays. The functional implications of a given concentration of t-PA antigen detectable with ELISA assays utilizing polyclonal anti-t-PA IgG may require interpretation in terms of the specific t-PA forms present in plasma at the time of assay. Accordingly, the propensity for reocclusion in high-risk patients may be underestimated when evaluated solely in terms of plasma t-PA concentrations quantitated by current methods. These findings indicate that ELISA assays that utilize monoclonal antibodies specific for the active site of t-PA or "free" t-PA may be more useful in estimating the prevailing level of t-PA activity after infusions.30' 31 The activity of PAI-1 exhibited considerable variability among patients with infarction receiving infusions of t-PA. The striking elevation of free PAI-1 activity within 24 hr of infusions in 47% of patients is impressive considering that additional PAI-1 associated with pharmacologically administered t-PA is not quantitated by this assay. Also, residual free t-PA prevents quantitation of PAI-1 activity, with an estimated half-life of 7 min,18 during infusions and for the first hour after termination of infusions. Average free PAI-1 activity was not significantly different after infusions when compared with pretreatment values or values in patients with infarction who did not receive t-PA. However, this evaluation alone underestimates the prevailing level of t-PA inhibition unless PAI-1 associated with t-PA is considered. Our present study indirectly quantitates PAI-1 complexed with t-PA with the use of fibrin autography and ELISA. Thus, the prevailing level of t-PA inhibition after infusions is greater than that represented by free PAI-1 activity alone. The implementation of immunoassays for PAI-1 that recognize both free and complexed PAI-1 may be helpful in quantitating total PAI-1 during and after infusions of t-PA.32
Increases in the t-PA-PAI-1 complex detected by fibrin autography and of PAI-1 activity detected spectrophotometrically may reflect circadian changes,33 the acute phase reactant nature of PAI-1l13 14 or both.
They probably do not reflect augmented release of PA1-1 into the circulation in response to infusion of t-PA. This interpretation is supported by our results in rabbits given t-PA in which increases of the t-PA-PAI-1 complex and free PAI-1 activity were not detected. Although species variability is a consideration, measurements of free PAI-1 activity in sequential plasma samples obtained from patients with infarction treated with t-PA and from hospitalized controls also favor this conclusion. Although the possibility cannot be excluded that SDS activation of latent plasma PAI-1 is responsible for increases in the t-PA-PAI-1 complex observed by fibrin autography, 34 35 such phenomena cannot explain the increases in free PAI-1 activity in plasma samples that are not exposed to SDS. Also, assay of PAI-1 activity and antigen in samples from different sources suggest that plasma PAI-1 is predominantly in an active form compared with PAI-1 in serum or liberated from platelets in vitro. 36 Accumulation of the t-PA-PAI-1 complex because of a longer circulating half-life compared with that of free t-PA or other t-PA-inhibitor complexes must also receive consideration as a cause of incqeases in the t-PA-PAI-1 complex detected in samples from patients given infusions of t-PA. Although Rijken and Emeis37 have demonstrated a longer circulating half-life for light-chain t-PA complexes with inhibitors than for intact t-PA in the rat, the clearance of complexes of t-PA with plasma inhibitors, including PAI-1, was as rapid as free t-PA.
Our findings suggest that elevated PAI-1 activity associated with myocardial infarction attenuates the fibrinolytic activity of substantial amounts of residual plasma t-PA after infusions of t-PA have been terminated. Thus, increased PAI-1 activity may contribute to the risk of coronary reocclusion. However, definition of its role requires further study and investigation of concomitant activation of the hemostatic system,38 platelets,39 and contributions of persistence of highgrade residual stenoses.5 Delineation of PAI-i activity may serve as a useful focus for titrating maintenance, low-dose infusions of t-PA designed to maintain coronary patency after initially successful clot lysis. 6, 40 Our results underscore the importance and potential clinical utility of characterizing, monitoring, and modulating PAI-1 activity and its interactions with t-PA as well as interactions of t-PA with other inhibitors that may influence fibrinolytic activity under specific clinical circumstances.
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